A US$38bn bridge loan backing US biopharmaceutical company abbvie's US$63bn bid for Botox-maker Allergan, and the additional bank business the merger will generate, have been welcomed with open arms by a US loan market starved of new lending opportunities. The fully underwritten 364-day bridge loan is the fourth largest US dollar bridge loan on record. It is also the second mega bridge loan in the healthcare sector in 2019, following Bristol myers' US$33.5bn bridge to fund the acquisition of Celgene.
展开▼
